For decades, menopause has been treated like a finish line: the hormones fade, the periods stop, and the ovaries are often written off as exhausted, obsolete organs. But a growing number of researchers are asking us to look again. They argue that even after menopause, the ovaries are not simply dead weight. They may still be producing important hormones, communicating with the rest of the body, and influencing how a woman ages. This is not just an academic debate. It has real implications for decisions that millions of women face, especially whether to have their ovaries removed during a hysterectomy or as protection against ovarian cancer. Walter Rocca, an epidemiologist and neurologist at the Mayo Clinic, has spent years studying the effects of ovary removal. His position is clear: unless there is a strong genetic or medical reason, such as a dangerously elevated risk of ovarian cancer, he believes removing healthy ovaries after menopause is inadvisable. “I am convinced until proven otherwise,” he says. That simple statement challenges a long-standing assumption that once childbearing is over, the ovaries have little left to offer. Instead, Rocca and others suggest, the postmenopausal ovary may be quietly working in the background, helping to maintain health in ways we are only beginning to understand.
It is true that the ovaries do not produce hormones with the same furious energy after menopause as they did during a woman’s reproductive years. Estrogen levels fall sharply, and ovulation stops. But the drop is not total. The ovaries continue to make small amounts of hormones, including androgens and possibly estrogen, and these residual levels may matter more than we thought. What remains unclear, says Stephanie Faubion, medical director of the Menopause Society, is exactly how long that contribution stays important. Is it five years after menopause? Twenty years? Forever? And does it vary from woman to woman? Faubion is honest about how much we do not know. “We just have huge gaps,” she says. Those gaps are not just academic curiosities. Doctors routinely counsel women to consider removing their ovaries at the time of hysterectomy, even after menopause, because ovarian cancer is so deadly and difficult to detect. But if the ovaries are still doing useful work, that calculation changes. Removing them might prevent one disease while increasing the risk of others, from heart disease to dementia. The problem is that the evidence is still incomplete, and women are left making decisions with a mix of fear, tradition, and incomplete science.
The picture is becoming more complicated, and also more fascinating, thanks to research on what actually happens inside the aging ovary. Cecilia Duncan, a researcher who studies ovarian aging, has been analyzing human ovarian tissue and finding clues that the postmenopausal ovary is not just quiet — it is changing. Her team found that protein patterns in older ovaries suggest a shift toward a more inflammatory environment. To understand what might be driving that shift, they turned to mice. In a study published in June in the journal Molecular Human Reproduction, they compared ovaries from young mice, reproductively older mice, and post-reproductive mice. Over time, genes linked to inflammation and immune activity became much more active, and the number of immune cells inside the ovary increased. In other words, the aging ovary may gradually become a hot spot of low-grade inflammation. That does not necessarily mean it becomes harmful in every woman, but it raises worrying possibilities. As Birgit Schilling, an aging researcher at the Buck Institute for Research on Aging who collaborated on the human ovary work, puts it, “We think that a lot of those changes may make the ovary more prone to age-related diseases like ovarian cancer.” This is significant because after menopause, a woman’s risk of heart disease, stroke, and osteoporosis climbs sharply. Researchers have long blamed the loss of estrogen, but Duncan’s work hints that the aging ovary itself might be sending pro-inflammatory signals that affect the whole body — not just the pelvic region where it sits.
At the same time, another line of research is complicating the story from a completely different angle. David Pépin, a reproductive biologist at Massachusetts General Hospital and Harvard Medical School, is exploring the possibility that the ovary does not simply fade away, but actively reorganizes itself to keep making hormones. His evidence comes from a surprising place: cats. Years after cats were given an experimental birth-control gene therapy that prevented their ovarian follicles from maturing, they were still producing normal, healthy levels of estrogen, testosterone, and inhibin. That should not have been possible. Follicles — the small sacs that hold and nurture eggs — are the primary engines of hormone production during the menstrual cycle. Without them, hormone levels should have fallen off a cliff. But they did not. In preliminary work that has not yet been published, Pépin and his team found that after the ovaries were eventually removed, another population of cells, called the stroma, seemed to have taken over the hormone-making job. The stroma is the connective tissue that holds the ovary together, the scaffolding that supports all the more famous structures inside. Pilot studies in mice have shown something similar. Pépin thinks he may have uncovered a natural backup system, one that helps preserve hormone production as follicles disappear. Scientists have long suspected that the stroma contributes to whatever hormones the postmenopausal human ovary still makes. Pépin’s work brings that suspicion to life. And it has a deeper message: estrogen is not the only hormone that matters at menopause. “We know so little about how the other ovarian hormones that are disrupted at menopause may contribute to health,” he says. Then he adds the line that ties it all together: “It is not a dead organ.”
If the postmenopausal ovary is both a source of possible harm, as Duncan’s work suggests, and a possible protector, as Pépin’s work suggests, then what should women and doctors actually do? The question is urgent, especially for the roughly hundreds of thousands of women who undergo hysterectomies every year. In many cases, surgeons offer to remove the ovaries at the same time, a procedure called bilateral oophorectomy. The selling point is simple: removing the ovaries eliminates the risk of ovarian cancer almost entirely. And ovarian cancer is a frightening disease, often diagnosed late and difficult to treat. But the ovaries are also not the only thing being removed. They are endocrine organs, and their removal plunges a woman into abrupt surgical menopause if she has not already gone through it, or strips away whatever residual hormones she still has if she has. Rocca’s view is relatively stark: “I am convinced until proven otherwise that removing ovaries even after menopause is not advisable.” His caveat matters, though. For women with mutations in BRCA1 or BRCA2, or with a strong family history of ovarian or breast cancer, the risk is so high that removal can be life-saving. But for the vast majority of women, the balance between protecting against ovarian cancer and protecting long-term health is much more delicate. Rocca and others see growing evidence that ovary removal may increase the risk of heart disease, osteoporosis, cognitive decline, and even Parkinson’s disease. The ovaries, even in their later years, appear to be woven into a woman’s overall health in ways that doctors are only beginning to appreciate. The problem is that the uncertainty is enormous. Faubion’s phrase, “huge gaps,” is not an exaggeration. All too often, these gaps mean that women are forced to make one of the most consequential health decisions of their lives based on incomplete data and outdated assumptions.
What does the future hold? Researchers are now asking questions that would have seemed odd just a generation ago. At what point does the aging ovary become more liability than asset? Is there a moment when the inflammation it produces outweighs the hormones it still supplies? And can we tell, in any individual woman, which way the scale is tipping? Duncan is particularly interested in that threshold. Her research raises the unsettling possibility that the ovary’s very aging might eventually turn it into a broadcaster of inflammatory signals. If so, keeping it forever may not be the right answer for every woman. Pépin, meanwhile, is interested in the opposite question: how long can the ovary hold on to its ability to make hormones, and can that ability be supported or restored? Both approaches share a fundamental insight: menopause is not a wall. It is a transition, and the organs involved in that transition continue to change, evolve, and possibly influence a woman’s body for years after her final period. This is a radically different way of thinking about aging. For a long time, medicine treated the postmenopausal ovary as a piece of obsolete equipment, something to be removed at the slightest excuse. Now, researchers are treating it as a living, active organ with its own identity, one that might be protective for some women and harmful for others. The scientific questions are complicated, but the human stakes are not. Women deserve better answers than “it’s probably safer to take everything out.” They deserve a nuanced understanding of what their bodies are actually doing, not just during their reproductive years but across their whole lives. As the research continues, one message is already clear: the ovary after menopause is not silence and emptiness. It is a place of ongoing biological activity, still negotiating the terms of its relationship with the woman who carries it. That is a humbling thought, and maybe a hopeful one. It suggests that the end of fertility is not the end of physiological meaning. The body is still talking. The postmenopausal ovary is still listening. And science is, at long last, beginning to listen too.
